Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05323747 · ClinicalTrials.gov registry record
Prospective Evaluation of a Commercially Available Hydrogel Spacer
A clinical trial of Prostate Cancer, sponsored by BioProtect.
- Completed
- Registry status
- 20
- Enrollment target
- 2
- Study locations
NCT05323747: Completed study of Prostate Cancer, sponsored by BioProtect.
NCT05323747 is a study of Prostate Cancer that has completed, run by BioProtect. The registered enrollment target is 20 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05323747, a study of Prostate Cancer, has completed, sponsored by BioProtect.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Dosimetry efficacy evaluation of the hydrogel spacer
Conditions Studied
Interventions
- OTHER Observation
Study Locations (2)
California
- Western Radiation Oncology - Campbell
Nevada
- Northern Nevada Radiation Oncology - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2022-02-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05323747
The ClinicalTrials.gov registry entry for NCT05323747 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The listed sponsor is BioProtect, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT05323747 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Nevada.
Frequently Asked Questions
What is clinical trial NCT05323747 about?
NCT05323747 is a clinical study titled "Prospective Evaluation of a Commercially Available Hydrogel Spacer". Dosimetry efficacy evaluation of the hydrogel spacer
What is the current status of trial NCT05323747?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2020-11-20. Estimated completion is 2022-02-08.
What conditions does trial NCT05323747 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05323747?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT05323747?
This trial is sponsored by BioProtect, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05323747 being conducted?
This trial has 2 study locations across California, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.